相关实验视频

Updated: Jan 10, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

复发性/耐药性急性髓性白血病的CAR-DC与CAR-T治疗相结合:研究进展和未来前景

Rui Zhang¹, Jinlin Zhang², Hongkai Zhang³

¹Department of Hematology, Tianjin First Central Hospital, Tianjin, China.

Clinical and translational medicine

|November 26, 2025

概括

化学抗原受体T细胞疗法向C型莱克类分子-1显示出急性髓性白血病的前景. 将CAR-T细胞与CAR-engineered树突细胞结合起来,可以克服抗原逃逸并改善复发性/耐药性AML的结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

尽管目前的治疗方法,急性髓性白血病 (AML) 的复发率很高.
化学抗原受体T (CAR-T) 细胞疗法向C型乳素样分子-1 (CLL1) 显示了复发/耐药 (R/R) AML 的潜力.
现有的CLL1CAR-T疗法面临挑战,包括抗原逃逸和免疫抑制瘤微环境 (TME).

研究的目的:

为了解决CLL1CAR-T细胞治疗在R/RAML中的局限性.
提出一种新的组合策略,使用CAR-engineered树突细胞 (CAR-DCs) 与CLL1 CAR-T细胞.
探索这种综合方法的协同机制和未来前景.

主要方法:

临床试验和关于树突细胞 (DC) 治疗和CAR-DC治疗的基础研究的综述.
与CLL1 CAR-T细胞相结合的CAR工程直流电源的合成.
分析诸如抗原逃逸和TME调制等挑战.

主要成果:

针对R/RAML的CLL1向治疗已经显示出验证,但需要改进.
CAR-DCs可以增强抗原交叉呈现,激活内源性T细胞对抗原阴性克隆,并分泌免疫刺激性细胞因子.
CAR-DC可以维持CAR-T的活动并重塑TME.

结论:

将CAR-DC与CLL1CAR-T细胞结合起来,提供了一种有前途的策略,以克服R/R AML中的抗原逃逸和TME相关挑战.
优化CAR设计,管理毒性和建立临床方案是未来的关键方向.
这种协同方法有可能改善R/RAML的缓解率和患者结局.

关键词:

在CAR-DCs中使用.CLL1 卡特-T 汽车急性髓性白血病急性骨髓性白血病

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...